Error message

User warning: The following module is missing from the file system: admin_menu. For information about how to fix this, see the documentation page. in _drupal_trigger_error_with_delayed_logging() (line 1138 of /mnt/stor8-wc1-dfw1/408138/


7/14 3:18pm
Medical Marijuana, Pharmaceuticals
FDA approves first marijuana-derived drug
This is the first FDA-approved drug derived from marijuana. ... in terms of pharmaceuticals, clustered around the acceptance of medical marijuana.
7/14 7:18am
APH.V Cannabis, Pharmaceuticals
Better Marijuana Stock: Aphria vs. GW Pharmaceuticals
Which stock wins in a one-on-one matchup between two of the cannabis industry's multibillion-dollar companies?
7/14 7:18am
APH.V Cannabis, Growers, Medical Marijuana, Pharmaceuticals
Better Marijuana Stock: Aphria vs. GW Pharmaceuticals
Motley Fool Better Marijuana Stock: Aphria vs. GW Pharmaceuticals Motley Fool Aphria (NASDAQOTH:APHQF) and GW Pharmaceuticals (NASDAQ:GWPH) are both in the medical marijuana industry. However, the companies have very different business models. Aphria ranks among the largest cannabis growers in Canada, while GW ...
7/13 11:34am
Investors, Pharmaceuticals
Here's Why Marijuana Stock GW Pharmaceuticals Fell 13.3% in June
Investors learn that not every FDA drug approval creates a stock pop.
7/12 10:10am
Cannabis, Pharmaceuticals
Zogenix's seizure drug clears late-stage trial, shares soar
Zogenix Inc said on Thursday its drug to treat a rare form of childhood epilepsy reduced convulsive seizures in a second late-stage trial, sending the drug developer's shares up as much as 26 percent. The successful trial takes the company one step closer to bringing the drug to the market, and comes close on the heels of regulatory approval for GW Pharmaceuticals Plc's cannabis-based treatment for the same form of epilepsy. Current treatment options for Dravet syndrome, which affects an estimated 20,000 patients in the United States, are limited to a combination of seizure medication and drugs to prevent emergencies.
7/12 9:58am
ABT Pharmaceuticals
Can Established Pharmaceuticals Up Abbott (ABT) Q2 Earnings?
According to Abbott (ABT), key emerging markets represent the most attractive long-term growth opportunities for its branded generics product portfolio within EPD.
7/12 7:15am
ARNA Biotechnology, Pharmaceuticals
Free Pre-Market Technical Recap on ArQule and Three Additional Biotech
On Wednesday, July 11, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Eight out of nine sectors ended Wednesday's trading session in bearish territories. Taking into consideration yesterday's market sentiment, assessed the following Biotechnology equities this morning: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), ArQule Inc. (NASDAQ: ARQL), Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR), and Atara Biotherapeutics Inc. (NASDAQ: ATRA).
7/11 7:12am
News, Pharmaceuticals
Governor signs bill approving first medicine made from marijuana submitted by /u/Ventury1 [link] [comments]
7/11 7:12am
News, Pharmaceuticals
Governor signs bill approving first medicine made from marijuana submitted by /u/Ventury1 [link] [comments]
7/10 8:30am
ARNA Pharmaceuticals
Arena Pharmaceuticals Appoints Life Sciences Industry Veteran Kieran T. Gallahue to Board of Directors
SAN DIEGO, July 10, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA), a biopharmaceutical company focused on delivering novel, transformational medicines across multiple therapeutic areas, today announced the appointment of Kieran T. Gallahue as a non-executive director. Mr. Gallahue is a highly accomplished executive with over 25 years of leadership experience in publicly-traded life sciences companies. "We are thrilled to have Kieran join our board of directors," said Tina Nova, Chairman of the Board of Directors of Arena.
7/10 8:20am
ENDP Research, Pharmaceuticals
Today's Research Reports on Trending Tickers: Endo International and GW Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / July 10, 2018 / U.S. equities continued to push higher on Monday, as strong economic data counters worries on rising trade tensions. The Dow Jones Industrial Average advanced ...
7/05 5:01am
CNBX Cannabis, Pharmaceuticals
The Consumption of Cannabis As A Medicine For Cancer: An Exclusive Interview With Cannabics Pharmaceuticals Eyal Barad
submitted by /u/BestAtTeamworkMan [link] [comments]
7/03 10:31am
Nektar’s Immuno-Oncology Clinical Trial Collaboration with Syndax
Nektar Therapeutics (NKTR) and Syndax Pharmaceuticals (SNDX) have entered a collaboration for the evaluation of the efficacy and safety of the combination therapy of Nektar’s CD122-biased agonist NKTR-214 and Syndax’s small molecule Class 1 specific HDAC inhibitor entinostat for the treatment of patients suffering from metastatic melanoma that have previously reported treatment progression with an anti-PD-1 (programmed death receptor-1) agent. The recently presented preclinical study results showed that the NKTR-214+entinostat combination therapy significantly inhibited tumor growth in kidney and colon cancers. The trial will focus on establishing the recommended dosage of the combination therapy in the Phase 1b stage.
7/03 10:24am
Cannabis, CBD, Food, Pharmaceuticals
The DEA Is Rescheduling Epidiolex, But Not (Yet) Cannabis Or CBD
The U.S. Food and Drug Administration (FDA) last week made history: By giving approval for U.K.-based GW Pharmaceuticals PLC-ADR (NASDAQ: GWPH) application to market Epidiolex (to medically treat severe forms of epilepsy), it marked the FDA's groundbreaking admission that cannabis has medical value. For now, Epidiolex itself remains illegal for sale, pending the DEA's scheduling decision (likely as Schedule IV), due by September 23.
7/03 10:20am
CBD, Pharmaceuticals
U.S. Total CBD Market By Sector (in Millions)
The FDA last week approved UK-based GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH ) Epidiolex, a "pure plant-derived CBD" extract shown to drastically reduce seizures in children with epileptic ...
7/03 3:37am
Cannabis, Food, Pharmaceuticals
GW Pharma Receives Regulatory Go Ahead: Should You Buy?
People vouching for marijuana legalization have been celebrating the recent green flag by the Food & Drug Administration (FDA) for the cannabis-based drug, Epidiolex. GW Pharmaceuticals (NASDAQ: GWPH), a London headquartered company is producing a drug for the treatment of epilepsy that uses cannabidiol, specifically for people suffering from Lennox-Gastaut and Dravet syndromes. Here we use TipRanks data to take a closer look at what Wall Street’s top analysts see in store for this volatile stock.
7/02 9:02am
CF Pharmaceuticals
Vertex's Shares Rally as a Rival's CF Candidate Disappoints
Vertex Pharmaceuticals' (VRTX) stock rallies on disappointing study results on rival Galapagos' cystic fibrosis candidate. Vertex's third CF drug receives approval in Canada.
7/02 8:20am
ARNA Research, Pharmaceuticals
Today's Research Reports on Trending Tickers: BioMarin Pharmaceutical and Arena Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / July 2, 2018 / Major U.S. markets finished higher on Friday, but finished the week lower due to ongoing global trade concerns. The Dow Jones Industrial Average increased 0.23 ...
6/30 7:21am
Cannabis, Pharmaceuticals
This FDA Approval Creates a Cannabis Conundrum in the U.S.
The FDA approval of GW Pharmaceuticals' cannabidiol-based Epidiolex puts lawmakers in a precarious position.
6/29 4:52pm
ABBV Pharmaceuticals
Vertex Pops As Rival Disappoints In Cystic Fibrosis And AbbVie Opts Out
Vertex Pharmaceuticals shares rocketed to a three-month high Friday after rival Galapagos released disappointing for a cystic fibrosis treatment.
6/29 3:27pm
CARA, APH.V, ARNA Cannabis, Investing, Investment, Investors, Organic, Tobacco, Pharmaceuticals
Professional Financial Advisor recommended these stocks and his favorites
A friend of mine has 30k he wants to invest into cannabis stocks. His family is friends with a professional financial advisor who only works with 1 million dollar investors. My buddy went to him for advice and here's a list of his recommended investment portfolio and he highlighted(in Bold) which ones were favorites. Thought I would share this but i was shocked that Aphria wasn't even on the list!?? and others! Let's discuss. *In his portfolio below: If you were investing 1 million dollars into them, these are his percentages of each stock. Green Organic Dutchman Holdings 7.90% Aurora Cannabis 5.48\% Canopy Growth 5.25\% Cronos Group 5.23% MedReleaf 5.16% Hydropothecary 4.71% Canntrust Holdings 4.51% GW Pharmaceuticals 4.38\% Organigram Holdings 4.23% Emerald Health Therapeutics 3.38\% Auxly Cannabis Gro 3.33% Supreme Cannabis 2.71% Corbus Pharmaceuticals Holdings 2.59% Terrascend Corp 2.54% Newstrike Resources 2.11% Cann Group 2.05% Turning Point Brands 1.99% Radient Technologies 1...
6/29 12:19pm
Why Vertex Pharmaceuticals Incorporated Stock Surged 14% Today
The biotech gets a big win thanks to a potential competitor's pipeline disappointment.
6/29 10:53am
Galapagos: Silver Lining to Disappointing Study Data
Galapagos N.V. (GLPS) is falling on Friday, following disappointing data about its cystic fibrosis treatment. After the close of trading Thursday, Galapagos released disappointing data from the Phase 2 Pelican trial of its C2 corrector GLPG2737 in conjunction with Vertex Pharmaceuticals' (VRTX) Orkambi. Credit Suisse's Vamil Divan takes a look at the data today, writing that it "raises significant concerns about FALCON [trials] and the competitiveness of the entire cystic fibrosis franchise." He reiterated a Neutral rating on the shares.
6/29 10:25am
CBD, Food, News, Pharmaceuticals
CBD Medicine Developments Provide a Really Solid Base for GWPH Stock
Th U.S. Food and Drug Administration (FDA) approved Epidiolex June 25, a CBD medicine developed by GW Pharmaceuticals (NASDAQ:GWPH) that treats two rare forms of epilepsy. The adage about buying on rumor and selling on news definitely hit GWPH stock as it’s lost almost 10% of its value in the days following the historic announcement. “This is the first FDA-approved drug that contains a purified drug substance derived from marijuana,” stated the FDA’s June 25 press release.
6/29 8:11am
ABBV Pharmaceuticals
Benzinga's Daily Biotech Pulse: Gemphire On Fire, Acceleron-Celgene Taste Success, AbbVie Ditches Galapagos
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 28) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) Aptinyx Inc (NASDAQ: ...